Mark Walport

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mark Walport
Sir Mark Walport (8656569975).jpg
Born Mark Jeremy Walport
(1953-01-25) 25 January 1953 (age 61)[1]
London
Residence United Kingdom
Citizenship United Kingdom
Fields Immunology, Rheumatology
Institutions
Alma mater Clare College, Cambridge[1]
Thesis The biology of complement receptors (1986)
Doctoral advisor Peter Lachmann[2]
Known for
Notable awards
Spouse Julia Elizabeth Neild[1]
Website
twitter.com/uksciencechief
royalsociety.org/people/mark-walport

Sir Mark Jeremy Walport, FRS, FRCP, FRCPath, FMedSci (born 25 January 1953[1][6]), is a medical scientist and the Government Chief Scientific Adviser in the United Kingdom.[4][7][8][9][10][11][12][13]

Education[edit]

Walport is the son of a general practitioner and was born in London. He was educated at St Paul's School, London,[1] studied medicine at the University of Cambridge (Clare College) and completed his clinical training at Hammersmith, Guy's and Brompton Hospitals in London.[6][14] He was awarded a PhD for research into complement receptors under the supervision of Peter Lachmann in 1986 at the University of Cambridge.[15]

Career[edit]

Previously Walport was Director of the Wellcome Trust from 2003 to 2013.[3] Before this, he was Professor of Medicine (from 1991) and Head of the Division of Medicine (from 1997) at Imperial College London,[6] where he led a research team that focused on the immunology and genetics of rheumatic diseases.[16][17][18][19][20][21][22][23]

Honours[edit]

Walport was knighted in the 2009 New Year Honours list for services to medical research. He was elected a Fellow of the Royal Society in 2011.[5][6] His nomination for the Royal Society reads:

Mark Walport has an overwhelming case for election both for his earlier scientific work on the immunology of systemic LE and the role of complement and of defective apoptosis in its pathogenesis; and, as a general candidate, for his achievements as head of medicine at the Hammersmith Campus of Imperial College and since 2003 as Director of the Wellcome Trust. In the latter role he has provided national and international leadership at the highest level on biomedical research and policy issues and is widely recognised as a world leader in the promotion of biomedical science.[5]

References[edit]

  1. ^ a b c d e "WALPORT, Sir Mark (Jeremy)" (Who's Who 2013, A & C Black, an imprint of Bloomsbury Publishing plc, 2013; online edn, Oxford University Press). (subscription required)
  2. ^ Reed, Tanya (11 July 2003). "Wellcome to a new beginning". Reporter: The newspaper of Imperial College London (131). 
  3. ^ a b Vogel, G. (2003). "United Kingdom: Mark Walport to Take Reins at Wellcome Trust". Science 299 (5608): 803a–. doi:10.1126/science.299.5608.803a. PMID 12574591. 
  4. ^ a b Callaway, E. (2012). "Britain names next chief science adviser: Immunologist Mark Walport, head of one of the world’s largest biomedical charities, will take on role in 2013.". Nature 487 (7405): 20. doi:10.1038/487020a. 
  5. ^ a b c "Sir Mark Walport FRS | Royal Society". Retrieved 2012-07-05. 
  6. ^ a b c d "Dr Sir Mark Walport". Debrett's People of Today. Retrieved 14 February 2012. 
  7. ^ Mayor, S. (2012). "Mark Walport will be next UK government chief scientific adviser, cabinet office announces". BMJ 345: e4621. doi:10.1136/bmj.e4621. PMID 22767620. 
  8. ^ Kain, K. H. (2010). "Funding scientific discovery: An interview with Sir Mark Walport". Disease Models & Mechanisms 3 (5–6): 265–267. doi:10.1242/dmm.005710. PMID 20427555. 
  9. ^ Anon (2012). "Good advice: The UK government's latest appointment offers hope for British science.". Nature 487 (7405): 5. doi:10.1038/487005b. 
  10. ^ Gibney, Elizabeth (29 June 2012). "New chief scientific adviser announced". Times Higher Education. 
  11. ^ Mark Walport from the Scopus bibliographic database
  12. ^ Sir Mark Walport in conversation with David Cleevely, Centre for Science and Policy (CSaP) University of Cambridge on YouTube
  13. ^ Boulton, G.; Rawlins, M.; Vallance, P.; Walport, M. (2011). "Science as a public enterprise: The case for open data". The Lancet 377 (9778): 1633. doi:10.1016/S0140-6736(11)60647-8. 
  14. ^ Morris, K. (2003). "Mark Walport". The Lancet 362 (9382): 498–499. doi:10.1016/S0140-6736(03)14090-1. 
  15. ^ Walport, Mark Jeremy (1986). The biology of complement receptors (PhD thesis). University of Cambridge. 
  16. ^ "Mark Walport, Ph.D.,MB. BChir. , Member, Scientific Board". Grand Challenges in Global Health. Retrieved 14 February 2012. 
  17. ^ Walport, M.; Foulkes, I.; Weissberg, P.; Morgan, D.; Nebhrajani, S. (2012). "Medical research: No catch to UK charity funding". Nature 482 (7385): 308. doi:10.1038/482308a. PMID 22337042. 
  18. ^ Collins, P. Y.; Patel, V.; Joestl, S. S.; March, D.; Insel, T. R.; Daar, A. S.; Scientific Advisory Board the Executive Committee of the Grand Challenges on Global Mental Health; Bordin, I. A.; Anderson, E. J.; Dhansay, M.; Phillips, C.; Shurin, R. I.; Walport, W.; Ewart, Y.; Savill, S. E.; Bordin, K.; Costello, S.; Durkin, S.; Fairburn, A.; Glass, A.; Hall, A.; Huang, M. M.; Hyman, V.; Jamison, B. J.; Kaaya, S.; Kapur, P. A.; Kleinman, D. J.; Ogunniyi, W.; Otero-Ojeda, M. A.; Poo, W.; Ravindranath, A. (2011). "Grand challenges in global mental health". Nature 475 (7354): 27–30. doi:10.1038/475027a. PMC 3173804. PMID 21734685. 
  19. ^ Yamada, T.; Dautry, A.; Walport, M. (2008). "Ready for avian flu?". Nature 454 (7201): 162. doi:10.1038/454162a. PMID 18615064. 
  20. ^ Pickering, M. C.; Warren, J.; Rose, K. L.; Carlucci, F.; Wang, Y.; Walport, M. J.; Cook, H. T.; Botto, M. (2006). "Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice". Proceedings of the National Academy of Sciences 103 (25): 9649–9654. doi:10.1073/pnas.0601094103. PMC 1476693. PMID 16769899. 
  21. ^ Brown, J. S.; Hussell, T.; Gilliland, S. M.; Holden, D. W.; Paton, J. C.; Ehrenstein, M. R.; Walport, M. J.; Botto, M. (2002). "The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice". Proceedings of the National Academy of Sciences 99 (26): 16969–16974. doi:10.1073/pnas.012669199. PMC 139253. PMID 12477926. 
  22. ^ Botto, M.; Fong, K. Y.; So, A. K.; Barlow, R.; Routier, R.; Morley, B. J.; Walport, M. J. (1992). "Homozygous hereditary C3 deficiency due to a partial gene deletion". Proceedings of the National Academy of Sciences of the United States of America 89 (11): 4957–4961. doi:10.1073/pnas.89.11.4957. PMC 49207. PMID 1350678. 
  23. ^ Taylor, P. R.; Carugati, A.; Fadok, V. A.; Cook, H. T.; Andrews, M.; Carroll, M. C.; Savill, J. S.; Henson, P. M.; Botto, M.; Walport, M. J. (2000). "A Hierarchical Role for Classical Pathway Complement Proteins in the Clearance of Apoptotic Cells in Vivo". Journal of Experimental Medicine 192 (3): 359–366. doi:10.1084/jem.192.3.359. PMC 2193213. PMID 10934224. 
Government offices
Preceded by
Sir John Beddington
Government Chief Scientific Adviser
2013–present
Incumbent
Cultural offices
Preceded by
Michael Dexter
Director of Wellcome Trust
2003–2013
Succeeded by
Jeremy Farrar